Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer

  • Authors:
    • Seiji Yano
    • Hideyasu Matsuyama
    • Hiroshi Hirata
    • Ryo Inoue
    • Hiroaki Matsumoto
    • Chietaka Ohmi
    • Koshiro Miura
    • Mutsunori Shirai
    • Norio Iizuka
    • Katsusuke Naito
  • View Affiliations

  • Published online on: June 1, 2006     https://doi.org/10.3892/or.15.6.1453
  • Pages: 1453-1460
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Understanding the molecular action of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, might allow us to perform more effective therapies for hormone-independent advanced prostate cancer. A DNA microarray study was undertaken to comprehensively analyze the alteration of levels of 1,081 genes after gefitinib treatment in androgen-independent PC3 and DU145 cells and androgen-dependent LNCaP cells. The proliferation of PC3, DU145 and LNCaP cells was significantly inhibited by 50.2%, 83.8% and 55.2%, respectively, 6 days after 10 μM gefitinib administration. Of the above 1,081 genes, we identified 23, 13 and 33 genes with significantly different expression in PC3, DU145 and LNCaP cells, respectively, 24 h after 10 μM-gefitinib exposure. Among the identified genes, only Quiescin Q6, a negative cell cycle regulator, was increased after gefitinib treatment in all three cell lines regardless of gefitinib sensitivity. Except for Quiescin Q6, there were no overlapping genes between PC3 and DU145 cells. However, levels of several oncogenes or proliferation-related genes were changed after gefitinib treatment in the 2 androgen-independent cell lines. We also identified 7 unique genes [glycyl-tRNA synthetase, interferon, α-inducible protein, stratifin, nuclear factor of κ light polypeptide gene enhancer in B-cells 1, dual specificity phosphatase 9, guanine nucleotide binding protein (G protein) β polypeptide 2, neural retina leucine zipper] whose levels were altered exclusively after gefitinib administration in gefitinib-resistant PC3 and LNCaP cells, but not in DU145 cells, suggesting that these 7 genes could be targets for overcoming gefitinib resistance. Collectively, our molecular profiling data will serve as a framework for understanding the molecular action of gefitinib for prostate cancer.

Related Articles

Journal Cover

June 2006
Volume 15 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yano S, Matsuyama H, Hirata H, Inoue R, Matsumoto H, Ohmi C, Miura K, Shirai M, Iizuka N, Naito K, Naito K, et al: Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep 15: 1453-1460, 2006
APA
Yano, S., Matsuyama, H., Hirata, H., Inoue, R., Matsumoto, H., Ohmi, C. ... Naito, K. (2006). Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer. Oncology Reports, 15, 1453-1460. https://doi.org/10.3892/or.15.6.1453
MLA
Yano, S., Matsuyama, H., Hirata, H., Inoue, R., Matsumoto, H., Ohmi, C., Miura, K., Shirai, M., Iizuka, N., Naito, K."Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer". Oncology Reports 15.6 (2006): 1453-1460.
Chicago
Yano, S., Matsuyama, H., Hirata, H., Inoue, R., Matsumoto, H., Ohmi, C., Miura, K., Shirai, M., Iizuka, N., Naito, K."Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer". Oncology Reports 15, no. 6 (2006): 1453-1460. https://doi.org/10.3892/or.15.6.1453